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Simple Summary: The number of interval colorectal cancers is an intermediate measure of the effec-
tiveness of a population-screening programme in decreasing colorectal cancer mortality. Differences
between interval and screen-detected cancers have been reported. Better characterization of colorectal
cancer to differentiate false-negative faecal immunochemical test results from true interval cancers
would help determine whether to focus more on the organizational aspects of a screening programme
or on stratifying colorectal cancer risk. This review provides a comprehensive overview of the
epidemiological, clinical, and molecular characteristics of interval colorectal cancers.
Abstract: Tumors that are not detected by screening tests are known as interval cancers and are
diagnosed clinically after a negative result in the screening episode but before the next screening
invitation. Clinical characteristics associated with interval colorectal cancers have been studied, but
few molecular data are available that describe interval colorectal cancers. A better understanding
of the clinical and biological characteristics associated with interval colorectal cancer may provide
new insights into how to prevent this disease more effectively. This review aimed to summarize
the current literature concerning interval colorectal cancer and its epidemiological, clinical, and
molecular features.
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1. Introduction
Colorectal cancer (CRC) screening based on faecal occult blood followed by colonoscopy
has been demonstrated to reduce CRC mortality [1]. Unlike other screenings, a premalig-
nant polyp can be detected and removed in some cases; thus, the incidence of CRC can be
decreased, albeit to a limited extent [2]. Most organized screening programmes currently
use the faecal immunochemical test (FIT) as the preferable screening method for CRC [2,3].
The goal of a screening programme is to detect the largest number of existing tumors in the
population before their clinical occurrence. Consequently, a key performance indicator of
an organized population-based screening programme is the monitoring of interval cancers.
Although interval cancers are inevitable in a screening programme, their number should
be as small as possible because a high proportion would decrease screening effectiveness.
Identification of clinical and molecular characteristics associated with interval CRC, in
contrast to screen-detected CRC, may provide new insights into how to prevent interval
CRC more effectively through improved risk stratification.
1.1. Interval Colorectal Cancer Definition
A screen-detected cancer is a cancer detected by endoscopic confirmation after a
positive test. By contrast, the World Endoscopy Organisation defines an interval CRC
as that diagnosed clinically after a negative test result in a screening episode and before
the next invitation to the programme [4] (Figure 1). In an FIT screening programme,
interval CRC can appear after a negative FIT or after a positive FIT followed by a negative
colonoscopy. An FIT interval CRC is a cancer detected after a negative faecal occult
blood screening test and before the next invitation is due (2 years). Post-colonoscopy
CRC (PCCRC) is a cancer diagnosed after a positive faecal occult blood test followed by
a colonoscopy without CRC and before the next recommended screening or surveillance
examination.
Recently, new guidelines on post-polypectomy surveillance have been published [5–7],
and all share the aim towards more selective and less frequent surveillance. Currently,
surveillance colonoscopy after three years is recommended in patients with “high-risk
findings”, comprising at least 1 adenoma ≥ 10 mm or with high-grade dysplasia, ≥5 ade-
nomas, or any serrated polyp ≥ 10 mm or with dysplasia (Figure 1). By contrast, patients
with “no high-risk criteria” do not require endoscopic surveillance and should be returned
to screening. These guidelines are based on recent evidence [8–12] showing that the long-
term CRC risk in patients with non-advanced neoplasia is not higher than that in the
general population. If organized screening is not available, the repetition of colonoscopy
10 years after a negative colonoscopy is recommended [13,14]. However, these guidelines
have been recently published; no previous standard definition for post-colonoscopy CRC
was available.
An interval CRC could arise because of the following [4]: a missed lesion (prior
examination adequate or prior examination negative but inadequate); a detected lesion not
resected or incompletely resected; failed biopsy detection; or a de novo rapid growth CRC).
In this review, we will focus on FIT interval cancer because of the greater uniformity in
the definition [15]. Given the known natural history of CRC, most interval cancers detected
within one or two years are likely due to a false-negative FIT result (Figure 1). However, if
an advanced preneoplastic lesion is missed by the FIT, a much shorter sequence for CRC
is possible. In this case, it will not be easy to decide whether to classify them as missed
lesions or new cancers.
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Figu 1. Causes of colorectal interv l canc rs. FIT interval cancer is caused by de ovo can er (true interval cancer) or
non-detected lesions (false-negative FIT results). A post-colonoscopy colorectal cancer is also caused by de novo cancer
(true interval cancer) or missed lesions, incompletely resected lesions and failed biopsy (false-negative results). a High-risk
findings: individuals with complete removal of at least 1 adenoma ≥10 mm or with high-grade dysplasia, or ≥5 adenomas,
or any serrated polyp ≥10 mm or with dysplasia according to current guidelines [5–7]. b Except for the need for a 2- to
6-month early repeat col noscopy following piecemeal endoscopic resecti n of polyps ≥20 mm.
1.2. Diagnostic Accuracy of Faecal Immunochemical Tests in CRC Screening
In a population-screening context, the FIT has a sensitivity of 86% and a specificity of
85% to detect CRC [16] and a sensitivity of 29% and a specificity of 97% to detect advanced
adenoma [17]. Thus, the FIT is much less sensitive for advanced adenomas. However, the
natural history of these lesions to CRC and programmatic screening are opportunities to
detect them [18]. The sensitivity is significantly higher for polyps with advanced histology,
a larger size, and a pedunculated shape, and lower for serrated lesions [19–28]. Some
studies [29–31] have evaluated the differences in the diagnostic performance of the FIT in
detecting neoplasia located in the proximal or right-sided colon (colon above the level of
the splenic flexure) versus the distal colon. The most r cent meta-analysis [29] reported that
the FIT had a lower sensitivity for detecting advanced adenomas located in the proximal
colon than for detecting lesions in the distal colon compared with colonoscopy. By contrast,
the sensitivity for detecting CRC located in the distal colon was comparable t that in the
proximal colon, unlike a previous meta-analysis study [30]. In a primary study with a
symptomatic population, no differences were found in the CRC sensitivity by location [32].
1.3. Episode Sensitivity in an FIT Screening Programme
CRC screening is intended to reduce CRC cancer mortality by detecting neoplasia at
an earlier stage. High sensitivity is needed for an FIT screening programme to fulfil its
purpose. Thus, the programme should have the minimum number of interv l cancers. The
sensitivity of an FIT screening programme can be determined by two methods: (1) interval
cancer proportion (detection method), which calculates the proportion of interval cancers
among all cancers; (2) proportional interval cancer rate (incidence method), which contrasts
the incidence of interval cancers with the expected population incidence rate without
screening. European Guidelines for Quality Assurance in CRC [33] recommend using the
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detection method. However, this method compares screen-detected cancers, which can
become symptomatic in a longer period than two years, with interval cancers, which are
diagnosed within two years by definition. Thus, the detection method can overestimate the
episode sensitivity, particularly when measuring a prevalent screening round. By contrast,
the incidence method, which is not affected by overdiagnosis or duration bias, can be
difficult to calculate because it uses the incidence rate without screening.
The objective of this article was to review the evidence of the epidemiological, clin-
ical and molecular characteristics of interval cancers in CRC. First, we reviewed the in-
terval CRC proportion identified in FIT population-based screening programmes and
summarized patient-related characteristics associated with interval cancer. Second, we
summarized all the evidence concerning the molecular characterization of interval CRC.
2. Methods
Search Strategy and Selection Criteria
For the first objective, reviewing the evidence of the epidemiological and clinical
characteristics of interval CRCs in population-based screening programmes, we used
a precision-maximizing search strategy using PubMed until December 2020 (https://
pubmed.ncbi.nlm.nih.gov/; accessed on 28 December 2020) to retrieve studies of interval
cancers after negative immunochemical testing in organized screening programmes. The
search terms included were as follows: (FIT* OR fecal immunochemical OR faecal immuno-
chemical OR immunochemical test) AND (mass screening OR population-based screening
program* OR organized screening program* OR programmatic screening) AND (“interval
cancer” OR “interval colorectal cancer”) AND (colorectal neoplasms OR colorectal cancer
OR bowel cancer). Twenty-three articles were individually reviewed to retrieve studies that
reported CRC occurrence within 1–2 years after a negative FIT in average-risk screening
populations. Additionally, the reference lists of selected studies were revised to identify
additional relevant studies. We excluded studies with guaiac faecal occult blood tests, with
fewer than 100 screen-detected CRC samples or with insufficient data to calculate the CRC
interval proportion. The study quality score of the 12 observational studies was analysed
according to the Newcastle-Ottawa criteria [34] (Table S1).
For the second objective, reviewing papers describing the molecular features of inter-
val CRC, a literature search was conducted using PubMed until December 2020. The search
terms included were as follows: (“interval colorectal cancer” OR postcolonoscopy OR
post-colonoscopy OR “interval cancer” OR I-CRC) AND colorectal cancer AND screening
AND (molecular OR genetic OR genomic OR biological OR mutation). Eighty abstracts
were individually reviewed to retrieve studies that determined the biological characteris-
tics of interval cancers (FIT or post-colonoscopy interval cancers). Articles were carefully
evaluated, and reference lists were examined to include further appropriate publications.
We excluded studies conducted only in hereditary cancer populations. The study quality
score of the 13 observational studies was analysed according to the Newcastle–Ottawa
criteria [34] (Table S2).
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3. Results
3.1. Interval CRC Proportion and Epidemiological and Clinical Characteristics of Interval CRC
Wieten et al. [35] published a systematic review and meta-analysis to determine
the incidence rates of interval CRC following the guaiac faecal occult blood test and
FIT in population-based CRC screening programmes. They found a higher incidence
rate of interval cancer after a negative guaiac faecal occult blood test than after the FIT
(34 vs. 20 interval CRCs per 100,000 person-years, respectively). Moreover, they reported
that for every FIT interval CRC, 2.6 screen-detected cancers were found. However, scarce
information on interval cancer characteristics was provided.
After a systematic literature search, 12 studies which reported interval CRC after a
negative FIT in an average-risk population were included, comprising 13,760,868 screening
participants overall. The quality of most studies was judged as high (Supplementary
Table S1), and all were cohort studies. The characteristics of the included studies are shown
in Table 1. More than half of the studies used a 20-µg Hb/g faeces faecal haemoglobin
positivity cut-off. The interval CRC proportion identified in screening using the FIT
ranged from 4.6% to 59.1%, and the proportional interval cancer rate ranged from 4.0%
to 25.0% (Table 1). FIT sensitivity might differ among studies because of, different cut-off
values set for test positivity, screening participation, study population, FIT brand [36], and
number and type (prevalent or incident) of screening rounds analysed. The interval cancer
proportion was higher in the first round of the FIT and improved in subsequent rounds.
The explanation for this finding is that, with every subsequent round, more cancers are
diagnosed; consequently, fewer CRCs are missed with the FIT. The global efficacy of an
FIT-based CRC screening programme depends on the cumulative sensitivity of repeated
tests every two years [31].
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Table 1 shows that nine of the twelve studies found that FIT interval CRC was more
frequently located in the proximal colon, a finding that is consistent with previous stud-
ies [35,49]. FIT interval cancers are approximately twice more likely to occur in the proximal
colon than in the distal colon compared with screen-detected CRCs [31]. Nevertheless,
Buron et al. [44] reported an increased incidence of interval CRC located not only in the
right colon but also in the rectum, likely because rectal bleeding is a symptom that alerts
the patient. Several reasons explain the difference in FIT sensitivity for right-sided versus
left-sided cancers. First, and as already mentioned above, these findings may be explained
by the morphology and characteristics of the proximal lesions (sessile or flat lesions), which
may be associated with less bleeding. Second, the FIT detects adenomas, which have a
larger size and pedunculated shape (frequently located in the distal colon) than sessile
serrated adenomas, which are usually flat and smaller (frequently located in the proximal
colon). Finally, faecal haemoglobin originating from a proximal lesion could be subjected
more to degradation during bowel passage, causing more false-negative results.
Six of ten studies that analysed differences in cancer incidence according to sex
reported a higher risk of interval cancer in women. Previous studies have already reported
lower test sensitivity in women [50,51]. Brenner et al. [50] observed that, at any cut-off of
the quantitative FIT, the sensitivity and positive predictive value for detecting advanced
neoplasia were substantially lower among women, partly explained by sex differences
in the prevalence of advanced colorectal neoplasia. Van Turenhout et al. [51] evaluated
whether sex differences in FIT sensitivity existed for CRC. They found that women had a
lower FIT sensitivity and a higher specificity for CRC than men. The reason was likely due
to the presence of larger and more advanced adenomas in men than in women (because it
increases the probability of bleeding). In this study, sex differences were not explained by
age or tumor location. By contrast, previous studies have suggested that right-sided CRCs
occur more frequently in women [52–54]. Hormonal factors and genetic changes [55–57],
such as sporadic microsatellite instability that occurs with ageing [58,59], may contribute
to a higher prevalence of right-sided CRC. Finally, these sex differences in sensitivity could
also be explained by the slower colonic transit time in women [60–62].
Interval CRC was also associated with advanced age in two of the studies. The reason
could be explained by elderly individuals having a higher risk for colorectal neoplasia [63,64]
and a higher frequency of right-sided neoplasia [65,66]. A discrepancy exists in the long-
term trend of detection rates between proximal neoplasia [31], likely due to failure of the
FIT to detect the increased presence of advanced adenomas in the proximal colon at older
ages, or proximal advanced lesions progressing to invasive CRC faster in older patients.
Although female sex and advanced age are associated with right-sided CRC, a recent
systematic review reported that the prevalence of sessile serrated polyps did not differ by
sex or age [67].
Finally, interval CRC was staged as more advanced in six of the studies, likely because
of more aggressive tumors. The advanced stage and higher mortality observed in interval
cancers could be explained by the effect of a delayed diagnosis mostly caused by false-
negative FIT results [39,68]. However, the worse prognosis associated with true interval
cancers could be related to fast-growing neoplasia.
The haemoglobin concentration influences risk prediction of an interval cancer [69,70].
However, in four of the studies, false negatives had an almost undetectable concentration
of faecal haemoglobin [42–46]. Similar to other previously reported studies [71], these
false-negative lesions would be missed regardless of the cut-off value for positive FIT
results. Thus, it is important to inform our target population to carefully monitor the
symptoms and avoid patients being falsely reassured by the FIT result [72].
3.2. Molecular Characterization of Interval CRC
3.2.1. Pathways of Tumorigenesis and Consensus Molecular Subtype (CMS) Classification
CRC is a heterogeneous disease comprising different molecular entities. Indeed, three
features classify CRC tumors from a molecular perspective [73]: (1) chromosomal instability
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(CIN) or the conventional adenoma-carcinoma pathway, (2) microsatellite instability (MSI)
and (3) the serrated polyp pathway exemplified by CpG island methylation ([CIMP]-high)
and BRAF mutation.
Microsatellite stable (MSS) tumors harbour chromosomal abnormalities, whereas
MSI tumors are hypermutant neoplasias. Both MSI and CIMP phenotypes can coexist in
the same tumor [74]. More recently, the CRC Subtyping Consortium defined novel CRC
molecular subtypes (CMSs) based on gene expression data (Figure 2). CMS1 (MSI immune)
includes tumors with a better prognosis that are associated with MSI and have immune
cell infiltration. CMS2 tumors (canonical) are characterized as microsatellite stable and
have activated WNT/MYC pathways. CMS3 (metabolic) tumors are mainly characterized
by activated pathways related to metabolism. Finally, CMS4 tumors (mesenchymal) show
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Figure 2. Characteristics of the molecular subtypes of colorectal cancer. CIMP: CpG island methylator
phenotype; CMS: consensus molecular subtype; EMT: epithelial–mesenchymal transition; MSI:
microsatellite instability; MSS: microsatellite stable.
3.2.2. Studies of Molecular C aracterization of Interval CRC
Although many interval cancers are c nsidered lesions t at were not detected at
previous colonoscopies or a previous FIT, few studies have investigated interval tumor
molecular characterization. To our best knowledge, only one study that has investigated
the molecular features of interval CRCs using guaiac faecal occult blood tests and none
using the FIT. We excluded studies performed only in patients with hereditary cancer. After
a systematic literature search, we included 13 studies that evaluated the biological and
genomic characteristics of interval CRCs (Table 2). All the studies were performed after a
diagnostic colonoscopy except Nishihara et al. [75] where the colonoscopy was a screening
test and Walsh et al. [49] performed in a guaiac-based screening programme. The PCCRC
definition most commonly used was a CRC detected within 60 months of a colonoscopy.
The quality of most studies was evaluated as high (Supplementary Table S2), and all were
cohort studies. The characteristics of the included studies are shown in Table 2. The largest
study that investigated the MMR status included 725 PCCRCs, and the largest study with
genomic analysis included 82 PCCRCs. The molecular features analysed were the presence
of MSI, CIMP, and CIN, and the most frequent mutations determined were BRAF and
KRAS. In reviewing the literature, no data were found on the molecular characteristics of
interval cancers according to CMS classification.
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Table 2. Studies that molecularly characterized interval cancer.
Author and
Year
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NOTE. Bold indicates studies that were performed in screening populations. The grey shadow refers to the direction of the association between the factor and interval cancers, only shown when the study
compares PCCRCs with DCRC cancers. a Adjusted by age; b Adjusted by size, location, and histology differentiation; c Adjusted by body mass index, smoking status, familiar history of CRC, aspirin, physical
activity level, red meat intake, caloric intake, alcohol intake, folate intake, calcium intake, multivitamin use, nonsteroidal antiinflammatory drug use, and cholesterol-lowering drug use; d OR and/or 95% not
available; e Adjusted by age, MSI, and location; f Adjusted by CIMP, MSI, BRAF, and KRAS. CIMP: CpG island methylator phenotype; CMS: consensus molecular subtype; CNI: chromosomal number instability;
CRC: colorectal cancer; DCRC: detected colorectal cancer; FAP: Familial adenomatous polyposis; IBD: inflammatory bowel disease; iCRC: interval CRC; gFOBT: guaiac faecal occult blood test; MMR mismatch
repair; MSI: microsatellite instability; NA: not available; PCCRC: post-colonoscopy colorectal cancer.
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PCCRCs and clinically detected CRCs appear to have different biological character-
istics, particularly regarding the presence of MSI. Among the six studies that analysed
differences in the cancer incidence according to the MMR status, five reported that more
PCCRCs displayed DNA mismatch repair deficiency than detected tumors. Some studies
also showed that interval cancers were more frequent in the proximal colon. Additionally,
MSI tumors were more likely than MSS cancers to occur in the proximal colon. These re-
sults, and the accelerated growth of small adenomas to invasive cancers due to MSI [86,87],
could explain de novo rapid-growth neoplasias.
Two of the three studies that analysed CIMP found that interval cancers were more
frequently CIMP-high. Furthermore, Arain et al. [77] and Sammadder et al. [84] stated
that CIMP-high tumors were more likely to occur in the proximal colon and were MSI.
CIN has only been analysed in the population of Winnipeg, and no association was found
with PCCRC, a finding that is consistent with CIN being a prominent feature of distal
cancers [88,89].
Studies evaluating the association between PCCRCs and the presence of mutations
have been negative. Only Shaukat et al. [79] found an inverse association of KRAS mutation
with interval cancer and the MSI status. Despite the known association in sporadic CRCs
between BRAF mutation and CIMP-high, none of the studies have shown its association
with PCCRCs. However, BRAF-mutated cancers were more likely to be MSI, poorly
differentiated, mucinous in histology and located in the proximal colon [78]. Moreover,
BRAF mutations and CIMP-high frequently coexisted [84].
In the English Bowel Cancer Screening Programme, Walsh et al. [49] investigated
the characteristics of screen-detected and guaiac faecal occult blood test interval CRCs.
They wanted to explore whether improved outcomes in screen-detected patients were
explained by biological differences. Interval cancers were larger and more frequent with
venous invasion. However, they found no differences in the proportion of MSI-high tumors,
vascularity or the tumor growth rate. They concluded that the low sensitivity of the guaiac
faecal occult blood test for CRC explained more interval CRCs than rapid growth and/or
reduced bleeding.
4. Discussion
The interval CRC proportion identified in screening using the FIT in population-
screening programmes is approximately 15%, slightly lower in successive screening rounds.
According to clinical characteristics, interval cancers are more likely to arise in women and
to be located in the right colon. At the molecular level, studies have shown that interval
cancer is MSI and CIMP-high.
The reported molecular features of PCCRC implicate the role of at least two specific
carcinogenic pathways, the MSI and serrated pathways. Additionally, overlapping of dif-
ferent carcinogenic pathways occurs. These differences reflect the molecular characteristics
already described in right-sided tumors [89]. However, insufficient data exist to differen-
tiate whether these characteristics are associated with missed tumors or de novo CRCs.
Studies have also shown genetic similarities between clinically detected CRCs and PCCRCs,
suggesting that interval CRCs could arise from missed sporadic lesions. The aetiology
of interval PCCRC is thought to be explained mostly by missed or incompletely resected
polyps on colonoscopy with some contribution from fast-growing new lesions [90–92].
Only one study performed in a stool-based screening programme using a guaiac-based
test assessed the molecular characteristics of interval CRC. Compared with guaiac-based
tests, FIT interval cancer might have fewer false-negative cancers and a higher frequency
of fast-growing advanced neoplasias given its higher sensitivity for advanced adenomas
and CRCs [3,93]. However, compared with PCCRC, more pedunculated lesions and distal
polyps are expected among false-negative cancers. In summary, as the sensitivity of a
screening test increases, the number of false-negatives decreases, and the proportion of
fast-growing tumors increases.
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Sessile serrated polyps are lesions more frequently missed, [94] with a higher rate
of incomplete resection during colonoscopy [95] and a lower susceptibility to bleed. The
reasons could be due to their proximal location, small size, flat or sessile morphology, and
endoscopic appearance (mucus cap and irregular shape) [95]. Thus, sessile serrated polyps
could be responsible for both PCCRCs and FIT interval cancers. Better understanding of
the disease biology of serrated polyps is needed to improve surveillance strategies focusing
on high-risk population. A strong relationship between serrated polyps and lifestyle
factors (particularly smoking) has been reported in the literature [96]. Consistent with this
finding, in a recent meta-analysis, smoking increased the risk of CRC characterized by MSI,
CIMP-high, and BRAF mutation [97]. Taken together, these data show that smokers are
susceptible to the development of interval cancers and may need a personalized strategy
of post-polypectomy surveillance.
Regarding CMS categorization, although no study has been reported in interval CRC, a
higher proportion of screen-detected cancers could be hypothesized to be CSM2 and CMS3
because the tumors have an adenoma-carcinoma 10-year interval and KRAS mutations. By
contrast, interval cancers would be classified mostly in CSM1/CMS4. These two categories
are good candidates to explain interval cancers for several reasons. First, both types are
proposed to arise from serrated lesions [98]. However, CMS1 tumors mainly comprise
MSI tumors enriched in the interval tumor setting [77]. Additionally, CMS4 tumors are
aggressive and frequently detected in late stages. Thus, they could be hypothesized to
have rapid growth that, in turn, might prevent them from being detected in a two-year
screening round.
Despite the heterogeneity of the studies that molecularly characterized interval cancer
and its small sample size, they all point in the same direction. However, further research
is needed, particularly regarding FIT screening, because we cannot translate these data
to interval CRC in FIT-based CRC screening. Although the study of Walsh et al. [49]
was performed in a screening programme, it used guaiac faecal occult blood test as the
screening test. Another limitation is that some of the studies in Table 2 did not exclude
patients with hereditary CRC. This observation is critical given that the most important
molecular feature analysed is the MMR status, which is characteristic of Lynch syndrome.
However, the higher median age of subjects in the studies indicates that most MSI cancers
were sporadic. Additional studies restricted to average-risk populations and in an FIT
screening programme setting are needed.
An FIT interval CRC could be explained by FIT sensitivity and factors that alter it.
However, in some cases, it could account for its own tumor characteristics (e.g., non-bleeding
or intermittent-bleeding neoplasia or de novo rapid growth CRC). The ability to differenti-
ate false-negative FIT results from true interval cancers would be very helpful. For example,
if most of the interval CRCs are false-negative results, we should investigate the underlying
factors (e.g., temperature [99,100] and subsequently implement improvements in screening
programmes (e.g., maintaining screening cold chains). However, if interval cancers are
rapid-growth neoplasias, efforts should be focused on developing new screening strategies,
such as stratifying CRC risk using the previous haemoglobin concentration, age or/and
sex. [101] Another example of better understanding the altered biology of interval cancers
to optimize screening programmes and post-polypectomy surveillance recommendations
would be to offer a simple recommendation to quit smoking. This finding is consistent
with the already mentioned relationship between cigarette smoking and interval cancer
molecular characteristics (MSI-high and serrated polyps).
5. Conclusions
Interval cancers are more likely to arise in women, to be located in the right colon,
to display a DNA mismatch repair deficiency and to be CIMP-high. Knowing the charac-
teristics associated with interval CRC as opposed to screen-detected CRC could improve
our understanding of the carcinogenic pathways and could prevent interval CRC through
risk stratification.
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